COMPANY PROFILE // THE 014 REPORT
IRulya Therapeutics Inc.
IRLA (Nasdaq) · Formerly: Quince Therapeutics, Inc.; Cortexyme, Inc.
Assembled from 3 government sources in 0.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber9 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-09: a pattern of leadership change.
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-09-04 and 1 more time (last 24 months).
- AmberNT 10-K filed on 2026-04-01: notice that a periodic report would be late.
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
IRulya Therapeutics Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in New Haven, CT; listed as IRLA (Nasdaq).[source] It has filed 90 documents with the SEC in the last 12 months; the latest is a S-8, filed 2026-11-19.[source] Its largest institutional holders on 13F filings are Balyasny Asset Management L.P., Ikarian Capital, LLC, MILLENNIUM MANAGEMENT LLC (as of 2026-06-30).[source] Seraphix flags 3 items from these records: 8-K Item 3.01 filed; 9 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-09; NT 10-K filed on 2026-04-01.[source]
- red0
- amber3
- info0
- Balyasny Asset Management L.P.$12.6M
- Ikarian Capital, LLC$1.3M
- MILLENNIUM MANAGEMENT LLC$1.3M
- Squadron Capital Management LLC$734K
- Shay Capital LLC$329K
- BOOTHBAY FUND MANAGEMENT, LLC$253K
- JANE STREET GROUP, LLC$230K
- VANGUARD CAPITAL MANAGEMENT LLC$219K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Hannah Brendan · CBO, COO & CCO (Officer) · latest Form 4 2026-01-23 · filing · LinkedIn search
- Ryan Charles S. · President (Officer) · latest Form 4 2026-01-23 · filing · LinkedIn search
- Thye Dirk · CEO and CMO (Director,Officer) · latest Form 4 2026-01-23 · filing · LinkedIn search
- Benatti Luca · Director · latest Form 4 2025-12-29 · filing · LinkedIn search
- Bray June · Director · latest Form 4 2026-01-21 · filing · LinkedIn search
- Lamond David · Director · latest Form 4 2026-01-21 · filing · LinkedIn search
- McLoughlin Margaret · Director · latest Form 4 2026-01-21 · filing · LinkedIn search
- Patni Rajiv · Director · latest Form 4 2025-06-06 · filing · LinkedIn search
- RYAN UNA S · Director · latest Form 4 2025-06-06 · filing · LinkedIn search
- Senner Christopher J. · Director · latest Form 4 2026-01-21 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001662774 | source |
| EIN | 90-1024039 | source |
| Connecticut business ID | 3476949 | record |
| Business address (SEC) | 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- EXELIXIS, INC. · Senner Christopher J.
- Kalaris Therapeutics, Inc. · PATTERSON LEONE D
- Nkarta, Inc. · PATTERSON LEONE D
- Polaryx Therapeutics, Inc. · Ryan Charles S.
- ROCKET PHARMACEUTICALS, INC. · Militello John
- Zymeworks Inc. · PATTERSON LEONE D
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-19 filing S-8 · SEC EDGAR
- 2026-11-13 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-11-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 144 · SEC EDGAR
- 2026-10-21 filing 144 · SEC EDGAR
- 2026-10-19 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-09 officer change 8-K items 5.02,5.03,7.01,8.01,9.01 · SEC EDGAR
- 2026-10-09 name change Name changed from Quince Therapeutics, Inc. · SEC EDGAR
- 2026-10-08 filing S-8 · SEC EDGAR
- 2026-10-06 officer change 8-K items 5.02,5.03,5.07,9.01 · SEC EDGAR
- 2026-10-02 filing DEFA14A · SEC EDGAR
- 2026-10-02 officer change 8-K items 5.02 · SEC EDGAR
- 2026-09-14 officer change 8-K items 2.01,5.02,9.01 · SEC EDGAR
- 2026-09-04 filing 8-K items 3.01 · SEC EDGAR
- 2026-08-27 officer change 8-K items 5.02 · SEC EDGAR
- 2026-08-25 filing Proxy statement · SEC EDGAR
- 2026-08-24 filing EFFECT · SEC EDGAR
- 2026-08-17 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-08-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-14 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-05 filing S-3/A · SEC EDGAR
- 2026-07-31 officer change 8-K items 5.02 · SEC EDGAR
- 2026-07-31 filing PRE 14A · SEC EDGAR
- 2026-07-31 filing S-3 · SEC EDGAR
- 2026-07-30 filing 8-K/A items 8.01,9.01 · SEC EDGAR
- 2026-06-26 filing 8-K/A items 3.03 · SEC EDGAR
- 2026-06-26 filing 8-K items 3.03,5.03,9.01 · SEC EDGAR
- 2026-06-11 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-11 filing D · SEC EDGAR
- 2026-06-11 filing D · SEC EDGAR
162 earlier entries
- 2026-05-21 filing 8-K items 8.01
- 2026-05-18 filing 8-K/A items 7.01,9.01
- 2026-05-18 officer change 8-K items 1.01,2.01,3.02,5.02,5.03,7.01,9.01
- 2026-05-11 filing Quarterly report (10-Q)
- 2026-04-28 filing 8-K items 8.01
- 2026-04-27 filing ARS
- 2026-04-27 filing DEFA14A
- 2026-04-27 filing Proxy statement
- 2026-04-22 officer change 8-K items 5.02
- 2026-04-17 filing PRE 14A
- 2026-04-17 filing S-8
- 2026-04-10 filing Annual report (10-K)
- 2026-04-09 filing 8-K items 3.03,5.03,9.01
- 2026-04-01 filing NT 10-K
- 2026-03-30 filing 8-K items 1.02,7.01,9.01
- 2026-03-20 filing 8-K items 3.01
- 2026-02-12 filing 8-K items 2.02,8.01
- 2026-02-02 officer change 8-K items 5.02
- 2026-01-29 filing 8-K items 8.01,9.01
- 2025-12-29 filing 144
- 2025-11-12 filing Quarterly report (10-Q)
- 2025-11-12 filing 8-K items 2.02,9.01
- 2025-10-17 filing 8-K items 7.01
- 2025-10-17 filing 424B5
- 2025-09-26 filing 8-K items 1.01,2.03
- 2025-08-11 filing Quarterly report (10-Q)
- 2025-08-11 filing 8-K items 2.02,9.01
- 2025-08-05 filing EFFECT
- 2025-08-05 filing 424B5
- 2025-08-01 filing CORRESP
- 2025-08-01 filing UPLOAD
- 2025-07-25 filing S-3
- 2025-07-16 filing 8-K items 7.01,8.01,9.01
- 2025-07-01 filing D
- 2025-06-23 insider First Form 3/4/5 on record for Hannah Brendan (CBO, COO & CCO)
- 2025-06-23 insider First Form 3/4/5 on record for Ryan Charles S. (President)
- 2025-06-23 insider First Form 3/4/5 on record for Thye Dirk (CEO and CMO)
- 2025-06-13 filing 8-K items 1.01,3.02,9.01
- 2025-06-06 insider First Form 3/4/5 on record for Benatti Luca (Director)
- 2025-06-06 insider First Form 3/4/5 on record for Bray June (Director)
- 2025-06-06 insider First Form 3/4/5 on record for Lamond David (Director)
- 2025-06-06 insider First Form 3/4/5 on record for McLoughlin Margaret (Director)
- 2025-06-06 insider First Form 3/4/5 on record for Patni Rajiv (Director)
- 2025-06-06 insider First Form 3/4/5 on record for RYAN UNA S (Director)
- 2025-06-06 insider First Form 3/4/5 on record for Senner Christopher J. (Director)
- 2025-06-05 filing 8-K items 5.07
- 2025-05-13 filing Quarterly report (10-Q)
- 2025-05-13 filing 8-K items 2.02,9.01
- 2025-04-23 filing ARS
- 2025-04-23 filing DEFA14A
- 2025-04-23 filing Proxy statement
- 2025-04-09 filing PRE 14A
- 2025-03-24 filing S-8
- 2025-03-24 filing 424B5
- 2025-03-24 filing Annual report (10-K)
- 2025-03-24 filing 8-K items 2.02,9.01
- 2024-12-27 filing 424B5
- 2024-12-26 filing EFFECT
- 2024-12-23 filing CORRESP
- 2024-12-23 filing UPLOAD
- 2024-12-18 filing S-3
- 2024-11-14 filing 8-K items 8.01
- 2024-11-13 filing SC 13D
- 2024-11-13 filing Quarterly report (10-Q)
- 2024-11-13 filing 8-K items 2.02,9.01
- 2024-08-13 filing Quarterly report (10-Q)
- 2024-08-13 filing 8-K items 2.02,9.01
- 2024-06-21 filing 8-K items 3.01
- 2024-06-06 filing 8-K items 5.07
- 2024-05-13 filing Quarterly report (10-Q)
- 2024-04-24 filing ARS
- 2024-04-24 filing DEFA14A
- 2024-04-24 filing Proxy statement
- 2024-04-11 filing PRE 14A
- 2024-04-01 filing S-8
- 2024-04-01 filing Annual report (10-K)
- 2024-02-15 officer change 8-K items 5.02
- 2024-01-29 officer change 8-K items 5.02
- 2024-01-05 filing 8-K/A items 9.01
- 2024-01-03 filing 8-K items 8.01
- 2023-12-22 filing 8-K items 1.02
- 2023-12-08 filing 8-K items 3.01
- 2023-11-14 filing Quarterly report (10-Q)
- 2023-10-26 officer change 8-K items 5.02
- 2023-10-23 officer change 8-K items 1.01,2.01,2.03,5.02,9.01
- 2023-09-06 officer change 8-K items 1.01,2.03,5.02
- 2023-08-10 officer change 8-K items 5.02
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-07-24 officer change 8-K items 1.01,2.02,2.03,3.02,5.02,7.01,8.01,9.01
- 2023-05-25 filing 8-K items 5.07
- 2023-05-15 filing Quarterly report (10-Q)
- 2023-04-14 filing ARS
- 2023-04-14 filing DEFA14A
- 2023-04-14 filing Proxy statement
- 2023-04-05 filing 8-A12B
- 2023-04-05 filing 8-K items 1.01,3.03,5.03,8.01,9.01
- 2023-04-04 filing PRE 14A
- 2023-03-28 officer change 8-K items 5.02
- 2023-03-15 filing S-8
- 2023-03-15 filing Annual report (10-K)
- 2023-03-03 officer change 8-K items 5.02
- 2023-01-30 filing 8-K items 2.02,2.05,8.01
- 2023-01-27 officer change 8-K items 1.01,5.02
- 2022-12-16 filing 8-K items 3.01
- 2022-11-09 filing Quarterly report (10-Q)
- 2022-09-30 officer change 8-K items 5.02
- 2022-08-09 filing Quarterly report (10-Q)
- 2022-08-01 filing 8-K items 2.02,5.03,8.01,9.01
- 2022-08-01 name change Name changed from Cortexyme, Inc.
- 2022-07-22 officer change 8-K items 5.02
- 2022-06-10 officer change 8-K items 1.01,2.03,5.02,5.07
- 2022-05-25 filing DEFA14A
- 2022-05-20 filing S-8
- 2022-05-20 officer change 8-K items 2.01,5.02
- 2022-05-19 filing 424B5
- 2022-05-17 filing EFFECT
- 2022-05-17 filing POS EX
- 2022-05-12 officer change 8-K items 1.01,2.02,3.02,5.02,9.01
- 2022-05-10 filing Quarterly report (10-Q)
- 2022-05-10 filing 8-K items 8.01,9.01
- 2022-05-02 officer change 8-K items 2.05,5.02
- 2022-04-27 filing DEFA14A
- 2022-04-27 filing Proxy statement
- 2022-03-15 officer change 8-K items 5.02
- 2022-03-04 filing POS AM
- 2022-03-01 filing S-8
- 2022-03-01 filing Annual report (10-K)
- 2022-02-07 filing POSASR
- 2022-02-02 officer change 8-K items 2.02,2.05,5.02,8.01
- 2022-01-26 filing 8-K items 8.01
- 2021-12-23 filing 8-K items 1.01,9.01
- 2021-12-23 filing 424B5
- 2021-10-29 filing Quarterly report (10-Q)
- 2021-10-26 filing 8-K items 8.01
- 2021-08-06 filing Quarterly report (10-Q)
- 2021-06-21 filing 8-K items 5.07
- 2021-05-18 filing 8-K items 1.01,2.03
- 2021-05-06 filing Quarterly report (10-Q)
- 2021-04-30 filing DEFA14A
- 2021-04-30 filing Proxy statement
- 2021-03-01 filing S-8
- 2021-03-01 filing Annual report (10-K)
- 2021-02-16 filing 8-K items 8.01,9.01
- 2021-02-10 officer change 8-K items 5.02
- 2021-01-26 filing 8-K items 2.02,8.01,9.01
- 2021-01-25 officer change 8-K items 5.02
- 2020-12-04 filing 8-K items 8.01
- 2020-11-12 filing Quarterly report (10-Q)
- 2020-08-14 filing Quarterly report (10-Q)
- 2020-06-10 filing 8-K items 5.07
- 2020-06-01 filing S-3ASR
- 2020-05-21 officer change 8-K items 5.02,9.01
- 2020-05-12 filing 8-K items 2.02,9.01
- 2020-05-12 filing Quarterly report (10-Q)
- 2020-04-30 officer change 8-K items 5.02
- 2020-04-22 filing DEFA14A
- 2020-04-22 filing Proxy statement
- 2020-04-13 filing EFFECT
- 2020-04-13 filing 424B3
- 2020-04-09 filing CORRESP
- 2020-04-08 filing UPLOAD
- 2020-04-07 filing Registration (S-1)
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-19 (within 7 days) S-8 filed
- 2026-11-13 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-13 (within 30 days) 10-Q filed
- 2026-10-19 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-09 (older) 8-K filed: Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-08 (older) S-8 filed
- 2026-10-06 (older) 8-K filed: Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-10-02 (older) DEFA14A filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:IRLA The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above; 5 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1662774 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | IRLA / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 901024039 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001662774 | SEC EDGAR / IRS |
| CUSIP | 22053A305 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001662774 | SEC EDGAR |
former name (shown apart, not merged) (5)
- former nameCortexyme Inc. · ClinicalTrials.gov
- former nameCORTEXYME INC · EPA ECHO facilities
- former nameCORTEXYME INC · EPA ECHO facilities
- former nameQUINCE THERAPEUTICS · EPA ECHO facilities
- former nameQUINCE THERAPEUTICS · EPA ECHO facilities
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$83,979,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 00:25 UTC | Report an error |
| Total assets (at 2025-12-31) | $93,523,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 00:25 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$35,714,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 00:25 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $5,809,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 00:25 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 00:25 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 00:25 UTC | Report an error |
| State of incorporation | DE | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 00:25 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 00:25 UTC | Report an error |
| Business address | 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 00:25 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 00:25 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$41,425,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 00:25 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $352,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-22 00:25 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-22 00:25 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $445,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 00:25 UTC | Report an error |
| Form D total offering amount (D filed 2026-06-11) | $7,387,671 | 2026-06-11 | D | as filed | 2026-11-22 00:25 UTC | Report an error |
| Form D total amount sold (D filed 2026-06-11) | $0 | 2026-06-11 | D | as filed | 2026-11-22 00:25 UTC | Report an error |
| Form D industry group | Biotechnology | 2026-06-11 | D | as filed | 2026-11-22 00:25 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2026-06-11 | D | as filed | 2026-11-22 00:25 UTC | Report an error |
| Form D date of first sale | 2026-05-18 | 2026-06-11 | D | as filed | 2026-11-22 00:25 UTC | Report an error |
| Plan (pension, plan no. 001) | QUINCE THERAPEUTICS, INC. 401(K) PLAN: 27 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-22 00:25 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001193125-26-460562
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$27,744,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001193125-26-460562 | 2026-11-22 00:25 UTC | Report an error |
| Cash and cash equivalents | $39,821,000 | at 2026-09-30 | 10-Q | 2026-11-13 | 0001193125-26-460562 | 2026-11-22 00:25 UTC | Report an error |
| Debt due in the next 12 months (from an earlier report) | $11,756,000 | at 2025-12-31 | 10-K | 2026-04-10 | 0001193125-26-151364 | 2026-11-22 00:25 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-19 Filing S-8 filed
- 2026-11-13 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-13 Filing 10-Q filed
- 2026-10-19 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-09 Filing 8-K filed: Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-08 Filing S-8 filed
- 2026-10-06 Filing 8-K filed: Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-10-02 Filing DEFA14A filed
- 2026-10-02 Filing 8-K filed: Item 5.02 officer or director change
- 2026-09-14 Filing 8-K filed: Item 2.01 acquisition or disposition; Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-09-04 Filing 8-K filed: Item 3.01 delisting notice
- 2026-08-27 Filing 8-K filed: Item 5.02 officer or director change
- 2026-08-25 Filing DEF 14A filed
- 2026-08-24 Filing EFFECT filed
- 2026-08-17 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-08-14 Filing 10-Q filed
- 2026-08-14 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-05 Filing S-3/A filed
- 2026-07-31 Filing 8-K filed: Item 5.02 officer or director change
- 2026-07-31 Filing PRE 14A filed
- 2026-07-31 Filing S-3 filed
- 2026-07-30 Filing 8-K/A filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-26 Filing 8-K/A filed: Item 3.03 rights of holders modified
- 2026-06-26 Filing 8-K filed: Item 3.03 rights of holders modified; Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2026-06-11 Filing 8-K filed: Item 5.07 shareholder vote
2 earlier entries
- 2026-05-26 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2016-05-01 Record plan effective date: QUINCE THERAPEUTICS, INC. 401(K) PLAN
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | Balyasny Asset Management L.P. | $12,560,897 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
| 2 | Ikarian Capital, LLC | $1,314,245 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
| 3 | MILLENNIUM MANAGEMENT LLC | $1,287,470 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
| 4 | Squadron Capital Management LLC | $734,421 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
| 5 | Shay Capital LLC | $329,272 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
| 6 | BOOTHBAY FUND MANAGEMENT, LLC | $253,041 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
| 7 | JANE STREET GROUP, LLC | $229,958 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | $219,080 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
| 9 | Cormorant Asset Management, LP | $100,009 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
| 10 | UBS Group AG | $86,039 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:25 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIRulya Therapeutics Inc. · exact legal name · sx:ctsos:3476949 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIRulya Therapeutics Inc. · exact legal name · sx:ctgov:h5bb6f8cb8ac9f329 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1662774.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001662774. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.